PE/Cyanine7 抗人 CD117 (c-kit) 抗体、PE/Cyanine7 anti-human CD117 (c-kit) Antibody详细如下: Description: CD117 is a 145 kD protein tyrosine kinase also known as c-Kit. It is a receptor for stem cell factor or c-Kit ligand. CD117 is expressed on pluripotent hematopoietic progenitor cells (approximately 1-4% bone marrow cells), mast cells, and acute myeloid leukemia cells (AML). CD117 binding of c-Kit ligand induces phosphorylation of CD117 and stimulates proliferation and survival of primitive hematopoietic stem cells as well as erythroid-committed and granulo-monocytic committed cells. Other Names:Stem cell factor receptor, c-kit, mast cell growth factor receptor, steel factor receptor Isotype:Mouse IgG1, κ Isotype Control:PE/Cyanine7 Mouse IgG1, κ Isotype Ctrl Reactivity:Human, Cross-Reactivity: Cynomolgus, Cattle (Bovine, Cow) Antibody Type:Monoclonal Host Species:Mouse Immunogen:MOLM-1 megakaryocytic cell line Formulation:Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA). Preparation:The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions. Storage & Handling:The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. Application:FC - Quality tested Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Excitation Laser:Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm) Application Notes: The 104D2 antibody does not block binding of c-Kit ligand. Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunofluorescence microscopy1, and spatial biology (IBEX)4,5. Additional Product Notes:BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions. Application References: Broudy VC, et al. 1999. Blood 94:1979. (IF, IP) Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Nagano M, et al. 2007. Blood 110:151. (FC) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed Product Citations: Allan J, et al. 2017. Leuk Lymphoma. 10.1080/10428194.2017.1352089. PubMed Liao Y, et al. 2018. Stem Cells Transl Med. 0.659722222. PubMed Fang F, et al. 2020. Front Cell Dev Biol. 0.633333333. PubMed Ogaki S, et al. 2015. Sci Rep. 5:17297. PubMed Gall M, et al. 2015. Mol Cancer Ther. 14: 2595 - 2605. PubMed Grove K, et al. 2016. PLoS One. 11: 0145961. PubMed Serr I, et al. 2016. Nat Commun. 7:10991. PubMed Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed Skovdahl HK, et al. 2021. Frontiers in Pharmacology. 12:679741. PubMed Kerr BA, et al. 2021. Experimental Cell Research. 399(2):112456. PubMed Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed Thomas A, et al. 2021. Cancer Cell. 39(4):566-579.e7. PubMed Structure:Growth factor receptor with tyrosine kinase activity, subclass III, approximately 145 kD Distribution:Pluripotent hematopoietic progenitor cells (approximately 1-4% bone marrow cells), mast cells, acute myeloid leukemic cells (AML) Function:Growth factor receptor for stem cell factor. Induces proliferation and survival of primitive hematopoietic progenitors. Potent inducer of proliferation in erythroid-committed progenitor cells. Defects in CD117 have been linked to severe anemia and a decreased number of hematopoietic progenitor cells. Ligand/Receptor:c-Kit ligand Modification:Multiple phosphorylation sites Cell Type:Embryonic Stem Cells, Hematopoietic stem and progenitors, Leukemia, Mast cells, Mesenchymal Stem Cells Biology Area:Immunology, Stem Cells Molecular Family:CD Molecules Antigen References: 1. Giebel LB, et al. 1992. Oncogene 7:2207. 2. Furitsu T, et al. 1993. J. Clin. Invest. 92:1736.